ARKLIGN LABORATORIES, INC. – Trademark Portfolio
Entity Type: 03
ARKLIGN LABORATORIES, INC. holds 3 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 10 (Medical Apparatus) — 3 filings in this category. The portfolio also extends into Class 41 (Education & Entertainment) across 4 Nice Classification classes. Currently, 2 trademarks are registered and 1 is pending. Notable registered marks include GUM HERO and ARKLIGNERS. The owner is based in San Jose, CA.
2526 Qume Dr STE 15
San Jose, CA 95131
Showing of trademarks Trademarks
Trademark Classifications
ARKLIGN LABORATORIES, INC.'s trademark portfolio spans 4 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Education; providing of training; entertainment; sporting and cultural activities
Medical services; veterinary services; hygienic and beauty care for human beings or animals
Frequently Asked Questions
How many trademarks does ARKLIGN LABORATORIES, INC. have?
ARKLIGN LABORATORIES, INC. has 3 U.S. trademarks filed with the USPTO. Of these, 2 registered, 1 pending.
What trademark classes does ARKLIGN LABORATORIES, INC. file in?
ARKLIGN LABORATORIES, INC. files trademarks across 4 Nice Classification classes. The most active classes are Class 10 (Medical Apparatus), Class 41 (Education & Entertainment), Class 44 (Medical Services), Class 40 (Treatment & Processing). Class 10 covers surgical, medical, dental and veterinary apparatus and instruments.
What are ARKLIGN LABORATORIES, INC.'s most well-known trademarks?
ARKLIGN LABORATORIES, INC.'s registered trademark portfolio includes well-known marks such as GUM HERO and ARKLIGNERS. These are among 2 currently registered trademarks in the portfolio.
What is ARKLIGN LABORATORIES, INC.'s trademark registration success rate?
ARKLIGN LABORATORIES, INC. has a 100% trademark registration rate, with 2 out of 2 resolved applications resulting in successful registration. Currently, 1 application is pending review.